India, July 29 -- Shares of Novo Nordisk A/S (NVO) were plunging around 21 percent in Denmark as well as around 20 percent in the pre-market activity on the NYSE, after the Danish drug major on Tuesday lowered its sales and operating profit growth outlook for 2025. This was despite reporting higher profit and sales in its second quarter.
According to the company, the lowered sales outlook for 2025 is driven by lower growth expectations for the second half, related to weak growth expectations for Wegovy in the US obesity market, lower growth expectations for Ozempic in the US GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO markets.
For fiscal 2025, Novo Nordisk now expects operating profit growth t...